Gracell Biotechnologies Inc. (GRCL) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GRCL Hot Sheet
Join SI Premium – FREE
Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q2 EPS of ($0.29), $0.15 worse than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Innoviva (INVA) Misses Q3 EPS by 156c
- NewAmsterdam Pharma Company N.V. (NAMS) Tops Q3 EPS by 35c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
